KR20200051789A - Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질 - Google Patents

Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질 Download PDF

Info

Publication number
KR20200051789A
KR20200051789A KR1020207010605A KR20207010605A KR20200051789A KR 20200051789 A KR20200051789 A KR 20200051789A KR 1020207010605 A KR1020207010605 A KR 1020207010605A KR 20207010605 A KR20207010605 A KR 20207010605A KR 20200051789 A KR20200051789 A KR 20200051789A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207010605A
Other languages
English (en)
Korean (ko)
Inventor
그레고리 피. 창
앤 에프. 청
윌리엄 해니
브래들리 엠. 룬드
비앙카 프린츠
Original Assignee
드래곤플라이 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 드래곤플라이 쎄라퓨틱스, 인크. filed Critical 드래곤플라이 쎄라퓨틱스, 인크.
Publication of KR20200051789A publication Critical patent/KR20200051789A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207010605A 2017-09-14 2018-09-13 Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질 Ceased KR20200051789A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558510P 2017-09-14 2017-09-14
US62/558,510 2017-09-14
PCT/US2018/050916 WO2019055677A1 (en) 2017-09-14 2018-09-13 NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1)

Publications (1)

Publication Number Publication Date
KR20200051789A true KR20200051789A (ko) 2020-05-13

Family

ID=65723086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010605A Ceased KR20200051789A (ko) 2017-09-14 2018-09-13 Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질

Country Status (14)

Country Link
US (1) US20200277384A1 (https=)
EP (1) EP3681532A4 (https=)
JP (2) JP2020534269A (https=)
KR (1) KR20200051789A (https=)
CN (1) CN111432832A (https=)
AU (1) AU2018331412A1 (https=)
BR (1) BR112020005078A2 (https=)
CA (1) CA3075857A1 (https=)
EA (1) EA202090718A1 (https=)
IL (1) IL273206A (https=)
MA (1) MA50255A (https=)
MX (1) MX2020002880A (https=)
SG (1) SG11202002298PA (https=)
WO (1) WO2019055677A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019178364A2 (en) * 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2020081841A1 (en) 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
AR119393A1 (es) * 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
MX2022004430A (es) * 2019-10-15 2022-07-19 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
MX2022013944A (es) * 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
KR20230008157A (ko) * 2020-05-06 2023-01-13 드래곤플라이 쎄라퓨틱스, 인크. 항체 표적화 clec12a 및 이의 사용
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
PE20241789A1 (es) * 2021-04-26 2024-09-06 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
CN117106086A (zh) * 2022-08-09 2023-11-24 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115198A1 (en) * 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
EP1909832A4 (en) * 2005-06-29 2010-01-13 Univ Miami ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
WO2010080124A2 (en) * 2008-12-18 2010-07-15 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP3470431A1 (en) * 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
WO2017125897A1 (en) * 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
CN120173123A (zh) * 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白

Also Published As

Publication number Publication date
MA50255A (fr) 2021-05-26
JP2024099539A (ja) 2024-07-25
CN111432832A (zh) 2020-07-17
BR112020005078A2 (pt) 2020-10-13
SG11202002298PA (en) 2020-04-29
EA202090718A1 (ru) 2020-07-01
JP2020534269A (ja) 2020-11-26
CA3075857A1 (en) 2019-03-21
AU2018331412A1 (en) 2020-03-26
MX2020002880A (es) 2020-10-01
US20200277384A1 (en) 2020-09-03
EP3681532A1 (en) 2020-07-22
EP3681532A4 (en) 2021-09-01
WO2019055677A1 (en) 2019-03-21
IL273206A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7431392B2 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
US20210261668A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
KR20200051789A (ko) Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질
KR102835308B1 (ko) Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
KR20190123299A (ko) Caix, ano1, 메소텔린, trop2, cea, 또는 클라우딘-18.2를 표적화하는 다중특이적 결합 단백질
KR20200010428A (ko) Nkg2d, cd16, 및 ror1 또는 ror2에 결합하는 단백질
JP2024012297A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
KR20200033302A (ko) Nkg2d, cd16 및 flt3에 결합하는 단백질
KR20190118172A (ko) 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20200038530A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
KR20190115469A (ko) Bcma, nkg2d 및 cd16에 결합하는 단백질
KR20190120782A (ko) Her2, nkg2d 및 cd16에 결합하는 단백질
KR20200010429A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
KR20190120775A (ko) Cd33, nkg2d 및 cd16에 결합하는 단백질
JP2022105121A (ja) Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
KR20190120781A (ko) Cd123, nkg2d 및 cd16에 결합하는 단백질
KR20190120783A (ko) Gd2, nkg2d 및 cd16에 결합하는 단백질
HK40062610A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200413

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210910

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231108

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D